- Algernon Pharmaceuticals has reported positive results from the complete data set of its Phase 2a Study evaluating NP-120 for the treatment of idiopathic pulmonary fibrosis and chronic cough
- All of the data showed positive results, including statistically significant improvements in measures of cough
- Christopher J. Moreau, CEO of Algernon Pharmaceuticals, sat down with Daniella Atkinson to discuss the update
- Algernon is a drug re-purposing company that investigates safe, already approved drugs, and naturally occurring compounds, for new disease applications
- Algernon Pharmaceuticals Inc. (AGN) opened trading at C$5.39per share
Algernon Pharmaceuticals (AGN) has reported positive results from the complete data set of its Phase 2a Study evaluating NP-120 (“Ifenprodil”).
Ifenprodil is being evaluated for the potential treatment of idiopathic pulmonary fibrosis (“IPF”) and chronic cough.
The full data set includes additional secondary measures of efficacy, including both objective measurement of lung function and patient-reported outcomes of both IPF and cough.
All of the data showed positive results, including statistically significant improvements in measures of cough.
Christopher J. Moreau, CEO of Algernon Pharmaceuticals, sat down with Daniella Atkinson to discuss the update.
“This data, when added to the topline data already reported, now provides a more complete picture that shows just how effective Ifenprodil was in this Phase 2a study. We look forward to presenting the data to the U.S FDA, including applying for orphan designation, the filing of a pre-IND application for a Phase 2b IPF with cough trial, as well as an application for Breakthrough Therapy designation.”
Algernon is a drug re-purposing company that investigates safe, already approved drugs for new disease applications.
Algernon Pharmaceuticals Inc. (AGN) opened trading at C$5.39.
